Skip to main content
. Author manuscript; available in PMC: 2009 Jun 1.
Published in final edited form as: Mol Cancer Ther. 2008 Jun;7(6):1506–1513. doi: 10.1158/1535-7163.MCT-07-2334

Figure 5.

Figure 5

In cells unable to mount a HIF response, CCI-779 increases resistance to 2-DG which correlates with increased ATP levels. (A, B) ATP assays in NSCLCA and C4 cells after exposure to various doses of 2-DG and 0.1μg/nl of CCI-779 under hypoxic conditions for 24h. Note the increase in ATP levels in both (A) NSCLC line A and (B) hepatoma (HIF−) cell line, C4, after treatment with CCI-779. Each data point is the average of triplicate samples with S.D. P<0.05.